Mutant KRAS in TNBC correlates with therapy resistance, reduced expression of estrogen receptor alpha (Erα), development of resistance to antiestrogen treatments, and negative prognostic outcomes, making it one of the pivotal factors in the progression of aggressive BC cases (18–20). Here, ESR1 is linked to breast cancer.